Japan Digital Therapeutics for Diabetes Market to Reach USD 136.44 Million by 2033 as AI Coaching, Remote Monitoring, Connected Devices, and Home-Based Diabetes Care Gain Momentum

Austin, Texas and Tokyo, Japan, May 2026 - DataM Intelligence has released its latest research report on the Japan Digital Therapeutics for Diabetes Market, identifying a high-growth opportunity for diabetes software companies, connected device manufacturers, remote monitoring platforms, pharmaceutical partners, CGM ecosystem providers, hospitals, specialty clinics, payers, investors, and Japan-USA digital health businesses.

According to DataM Intelligence, the Japan digital therapeutics for diabetes market reached USD 56.59 million in 2024 and is expected to reach USD 136.44 million by 2033, growing at a CAGR of 10.4% during 2025 to 2033. This creates an incremental market opportunity of USD 79.85 million across the forecast period. The market is segmented by product type into software solutions and hardware solutions, by application into type 1 diabetes, type 2 diabetes, and pre-diabetes, and by end user into hospitals, specialty clinics, homecare settings, and others.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/japan-digital-therapeutics-for-diabetes-market?kailas

The market is moving from basic digital tracking toward software-driven therapeutic support. Diabetes digital therapeutics use mobile apps, connected devices, wearables, glucose meters, and real-time data platforms to support blood glucose tracking, medication adherence, lifestyle management, diet guidance, activity monitoring, and personalized feedback. DataM Intelligence notes that these solutions collect real-time data from patient devices and use digital tools to provide continuous support and condition management.

For companies targeting Japan and the USA, the commercial signal is clear: Japan's diabetes care model needs scalable, lower-friction, home-based support that can complement physician care without increasing clinic workload. Digital therapeutics can help shift diabetes care from periodic appointments to continuous engagement, especially for patients who need daily behavioral guidance and long-term adherence support.

Market Outlook: From USD 56.59 Million in 2024 to USD 136.44 Million by 2033

The Japan digital therapeutics for diabetes market is projected to expand by approximately 141.1% between 2024 and 2033. Based on the reported 10.4% CAGR, the market is estimated to reach approximately USD 62.48 million in 2025, USD 68.97 million in 2026, USD 76.15 million in 2027, USD 84.07 million in 2028, USD 92.81 million in 2029, USD 102.46 million in 2030, USD 113.11 million in 2031, USD 124.88 million in 2032, and USD 136.44 million in 2033.

The growth case is supported by Japan's diabetes burden. DataM Intelligence cites International Diabetes Federation data showing 11 million adults in Japan have diabetes, while the IDF's 2024 country data estimates 10.76 million adults aged 20 to 79 living with diabetes, 31.3% undiagnosed diabetes, and USD 33.97 billion in diabetes-related health expenditure.

This creates a measurable need for digital solutions that can improve daily disease management, reduce avoidable clinical burden, and support early intervention. Japan's older population further increases demand because type 2 diabetes risk rises with age. Japan's Cabinet Office reported that people aged 65 and over reached 36.23 million in 2023, accounting for 29.1% of the total population.

Regulatory and Policy Impact: SaMD Reform Improves the Commercial Pathway

Digital therapeutics for diabetes are closely linked to Japan's broader Software as a Medical Device environment. Japan has been reforming its SaMD commercialization pathway to improve review predictability and accelerate practical use. The U.S. International Trade Administration reported that MHLW launched DASH for SaMD 2 in September 2023 to streamline commercialization and improve predictability for SaMD products.

PMDA materials on Japan's regulatory updates also describe the need to clarify commercialization paths, including a two-step approval scheme for SaMD, and to improve cooperation between regulatory and insurance authorities so companies can better understand approval and reimbursement direction.

This is important for diabetes DTx because the market depends on more than app downloads. Commercial adoption requires clinical validation, privacy compliance, physician confidence, reimbursement strategy, patient engagement, integration with devices, and regulatory clarity. DataM Intelligence also identifies privacy and security as a restraint, noting that companies must comply with Japan's Act on the Protection of Personal Information when handling sensitive health data.

Detailed Segmentation Analysis
By Product Type: Software Solutions Dominate Because Diabetes Care Requires Daily Behavioral Support

The product type segment includes software solutions and hardware solutions. DataM Intelligence identifies software solutions as the dominant product type, supported by mobile apps, digital platforms, AI-driven algorithms, personalized recommendations, glucose tracking, diet monitoring, physical activity tracking, and medication adherence features.

Software solutions are estimated to account for approximately 68.0% of the market in 2024, equal to nearly USD 38.48 million. By 2033, this segment is projected to reach approximately USD 98.24 million, increasing to around 72.0% share. Software dominates because the core value of diabetes DTx lies in continuous digital engagement. Patients need daily prompts, glucose insights, behavioral nudges, medication reminders, coaching, and feedback loops that can be delivered through smartphones and cloud-connected platforms.

The dominance of software is also linked to scalability. Once clinically validated and localized, software platforms can be deployed across homecare settings, clinics, and hospitals without the manufacturing complexity of device-heavy models. Software can also integrate with CGMs, smart insulin pens, glucose meters, diet logs, activity trackers, and physician dashboards.

Hardware solutions are estimated to account for approximately 32.0% of the market in 2024, equal to about USD 18.11 million. By 2033, hardware-linked revenue is projected to reach approximately USD 38.20 million. This segment includes connected glucose meters, CGMs, smart insulin pen caps, wearables, and device integrations that support data capture. Hardware remains important because diabetes DTx outcomes improve when apps receive accurate and continuous input data instead of relying only on manual user entry.

By Application: Type 2 Diabetes Leads Due to Japan's Aging and Lifestyle-Linked Disease Burden

The application segment includes type 1 diabetes, type 2 diabetes, and pre-diabetes. Type 2 diabetes is estimated to dominate the market with approximately 71.0% share in 2024, equal to nearly USD 40.18 million. By 2033, the segment is projected to reach approximately USD 95.51 million, maintaining around 70.0% share.

Type 2 diabetes dominates because it represents the largest patient pool and is closely tied to aging, diet, activity levels, obesity risk, and long-term medication adherence. Digital therapeutics are particularly relevant because type 2 diabetes management depends heavily on daily behavior, including meal choices, exercise, weight control, glucose monitoring, medication consistency, and long-term engagement.

Type 1 diabetes is estimated to account for approximately 16.0% of market revenue in 2024, equal to about USD 9.05 million. By 2033, type 1 diabetes DTx revenue is expected to reach approximately USD 20.47 million. The segment is smaller but clinically important because patients require more intensive glucose monitoring, insulin management, and device integration. Platforms that connect CGM data, insulin dosing history, activity, and diet can create meaningful value for type 1 diabetes patients and care teams.

Pre-diabetes is estimated to hold approximately 13.0% share in 2024, equal to nearly USD 7.36 million. By 2033, the pre-diabetes segment is expected to reach approximately USD 20.47 million, increasing to around 15.0% share. This is one of the most strategically attractive growth areas because digital therapeutics can intervene earlier through lifestyle coaching, weight management, meal tracking, activity guidance, and risk prevention. As payers and healthcare systems focus more on prevention, pre-diabetes solutions can become a high-value entry point.

By End User: Homecare Settings Become the Fastest-Growing Revenue Channel

The end-user segment includes hospitals, specialty clinics, homecare settings, and others. Hospitals are estimated to account for approximately 34.0% of market revenue in 2024, equal to nearly USD 19.24 million. By 2033, hospitals are projected to reach approximately USD 43.66 million.

Hospitals remain important because they manage complex diabetes cases, complications, specialist referrals, inpatient monitoring, and integration with broader chronic disease programs. However, hospitals are not expected to be the fastest-growing end-user segment because the most scalable digital therapeutic value is created outside hospital walls.

Specialty clinics are estimated to account for approximately 28.0% share in 2024, equal to about USD 15.85 million. By 2033, specialty clinics are expected to reach approximately USD 34.11 million. Diabetes clinics and endocrinology practices are important adoption points because they can prescribe, monitor, educate, and adjust care based on digital insights.

Homecare settings are estimated to account for approximately 30.0% of the market in 2024, equal to nearly USD 16.98 million. By 2033, this segment is projected to reach approximately USD 47.75 million, increasing to around 35.0% share. Homecare is the fastest-growing segment because diabetes management happens daily, not only during clinic visits. Patients benefit from app-based prompts, connected insulin tracking, remote monitoring, and coaching that can be used during meals, exercise, medication routines, and daily glucose checks.

Other end users, including payers, wellness programs, employers, pharmacies, and broader digital health ecosystems, are estimated to account for the remaining 8.0% share in 2024, equal to about USD 4.53 million, reaching approximately USD 10.92 million by 2033.

Competitive Landscape and Company Profiles
Health2Sync

Health2Sync is one of the most relevant companies in Japan's diabetes digital therapeutics ecosystem because it directly connects diabetes management software with insulin data integration. DataM Intelligence cites Health2Sync's March 2023 announcement that its latest app version integrated insulin data from Mallya Cap, the connected device dedicated to insulin pens developed by Biocorp and marketed in Japan by Novo Nordisk. The integration allows patients to capture insulin injection logs and combine them with blood glucose, diet, and lifestyle data for better diabetes management.

The Health2Sync, Novo Nordisk, and Biocorp partnership is commercially important because insulin adherence and dose tracking remain major pain points in diabetes care. The integration enables automatic collection of injection dosage, date, and time, which is then sent wirelessly to the Health2Sync app in real time.

Health2Sync's strongest Japan opportunity is in connected insulin management, personal health record integration, patient engagement, and data-driven diabetes coaching. Its model fits the market's shift toward software-led management supported by hardware data.

Welldoc

Welldoc is listed by DataM Intelligence among the major players in Japan's digital therapeutics for diabetes market. The company's diabetes platform is relevant because it focuses on digital coaching, AI-supported personalization, and provider-linked diabetes management.

Welldoc states that Welldoc Diabetes and Welldoc Diabetes Rx are FDA-cleared medical devices intended for healthcare providers and adult patients with type 1 or type 2 diabetes. Its platform is positioned around cardiometabolic care, including diabetes, pre-diabetes, hypertension, heart failure, weight and obesity management, mental wellbeing, and sleep support. The Digital Therapeutics Alliance notes that Welldoc has achieved 11 FDA 510(k) clearances for diabetes functionality and has an intellectual property portfolio of 42 patents.

Welldoc's strongest opportunity in Japan is in clinically credible, provider-supported diabetes coaching. As Japan's SaMD commercialization pathway becomes clearer, companies with strong regulatory experience and clinical evidence may be better positioned to partner with local healthcare systems.

Glooko

Glooko is another major player identified by DataM Intelligence in Japan's diabetes DTx market. The company's platform connects patients, providers, and devices to simplify diabetes care, streamline workflows, and deliver measurable health outcomes.

Glooko is strategically relevant because diabetes care requires integration across many devices and data sources. The platform supports remote patient monitoring, diabetes data management, and clinical workflow efficiency. For Japan, this matters because hospitals and specialty clinics need systems that reduce manual data review and help care teams manage larger diabetes populations without proportional increases in visit volume.

Glooko's strongest opportunity is in connected data infrastructure for diabetes care, especially where healthcare providers need dashboards, remote monitoring, device syncing, and scalable patient management.

Abbott Laboratories

Abbott is listed by DataM Intelligence among key players in the Japan digital therapeutics for diabetes market. Abbott's relevance comes from its strong diabetes technology position, particularly continuous glucose monitoring, which creates the data layer that digital therapeutic platforms can use to deliver personalized feedback and remote care.

In digital diabetes management, CGM and connected glucose data can turn software from a diary tool into an active management platform. For Japan, Abbott's opportunity is linked to CGM adoption, integration with apps, remote monitoring, and the shift from episodic glucose checks to continuous data-driven decision support.

Abbott's competitive value in this market is not only device supply. It is the ability to participate in broader digital ecosystems where glucose data connects with behavior, medication, clinical dashboards, and long-term diabetes outcomes.

Medtronic

Medtronic is also identified by DataM Intelligence as a key player in the market. The company is relevant through its diabetes technologies, including insulin delivery, monitoring, and connected care platforms. In digital diabetes therapeutics, Medtronic's role is strongest where software supports insulin management, patient monitoring, and data-based clinical decision-making.

For Japan, Medtronic's opportunity is tied to patients requiring insulin-intensive management and care models that combine device data with software support. As type 1 diabetes and insulin-treated type 2 diabetes patients adopt more connected care models, companies with both medical device expertise and software integration capabilities can gain strategic advantage.

Recent Developments
Health2Sync Integrated Mallya Cap Insulin Data in Japan

In March 2023, Health2Sync announced that its app integrated insulin data from Mallya Cap, a connected insulin pen cap developed by Biocorp and marketed in Japan by Novo Nordisk. The integration captures insulin dose, date, and time automatically and sends the data to the Health2Sync app in real time. This development strengthens the hardware-software integration model for diabetes DTx in Japan.

Japan Advanced DASH for SaMD 2 to Improve Commercialization Predictability

MHLW launched DASH for SaMD 2 in September 2023 to improve commercialization and predictability for SaMD products. PMDA materials also highlight the need to clarify commercialization pathways, including two-step approval for SaMD and coordination between regulatory and insurance authorities. This supports diabetes DTx companies seeking clearer routes to approval, adoption, and reimbursement planning.

Digital Therapeutics Adoption in Japan Continued Expanding Beyond Smoking and Hypertension

Japan's digital therapeutics market has already seen approved products in other therapeutic areas. JETRO notes that CureApp received Japan's first regulatory approval for its nicotine addiction treatment app in 2020 and later received approval for its hypertension management app in 2022. This matters for diabetes DTx because each approved DTx category helps build physician, regulator, payer, and patient familiarity with prescription software as a therapeutic tool.

Diabetes Burden Continues to Support Scalable Digital Care Models

The IDF estimates Japan had 10.76 million adults aged 20 to 79 with diabetes in 2024 and 3.37 million undiagnosed adults, with total diabetes-related health expenditure of USD 33.97 billion. This supports demand for scalable digital tools that can improve awareness, monitoring, adherence, and early intervention.

Data Privacy Remains a Key Commercial Requirement

DataM Intelligence identifies data privacy and security concerns as a restraint for Japan's digital therapeutics for diabetes market. Japan's APPI sets requirements for personal information handling, and the official Japanese law translation states that businesses handling personal information must report certain data leaks, loss, or damage events that may harm individual rights or interests. For diabetes DTx companies, privacy-by-design, consent management, secure storage, breach response, and healthcare data governance are not optional. They are market access requirements.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=japan-digital-therapeutics-for-diabetes-market?kailas

Why This Market Matters for Japan and USA-Focused Businesses

The Japan digital therapeutics for diabetes market is attractive because it combines chronic disease burden, high smartphone accessibility, rising comfort with digital health, SaMD regulatory reform, and strong need for home-based diabetes management. The market is expected to rise from USD 56.59 million in 2024 to USD 136.44 million by 2033, adding USD 79.85 million in new value.

For Japan-based companies, the strongest opportunities are in type 2 diabetes management, connected insulin tracking, CGM-linked coaching, pre-diabetes prevention, specialty clinic workflows, homecare support, and integration with national digital health initiatives. Companies that can prove better engagement, measurable glucose control support, lower clinical burden, and strong privacy compliance will be better positioned for adoption.

For USA-focused companies, Japan offers a defined opportunity for FDA-experienced DTx platforms, diabetes coaching apps, remote patient monitoring tools, connected device integration, AI-based behavior change engines, and provider dashboards. However, success will depend on localization, Japanese-language user experience, PMDA pathway strategy, physician adoption, reimbursement planning, APPI compliance, and partnerships with domestic healthcare organizations.

Conclusion

The Japan digital therapeutics for diabetes market is projected to reach USD 136.44 million by 2033, expanding at a 10.4% CAGR and creating USD 79.85 million in new market value from 2024 levels. Software solutions are expected to dominate, type 2 diabetes will remain the largest application area, and homecare settings are expected to deliver the fastest end-user growth.

The market's growth is being driven by measurable outcomes: improved daily self-management, better insulin data capture, reduced dependence on frequent in-person visits, stronger remote monitoring, earlier intervention for pre-diabetes, and more scalable support for Japan's large diabetes population. Companies that deliver clinically credible, privacy-secure, device-integrated, and patient-friendly diabetes DTx solutions will be best positioned to capture Japan's next phase of digital diabetes care.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence

DataM Intelligence provides market research and consulting insights across high-growth industries, helping organizations evaluate market size, competitive positioning, regulatory impact, customer demand, partner opportunities, and investment priorities. Its research supports business planning, market entry, product development, and strategic decision-making across global markets.

This release was published on openPR.